PetMed Express (PETS) Q1 2025 earnings summary

Executive summary

• Q1 FY2025 was a transition quarter marked by new executive leadership, including a new CEO and several C-suite hires, with a focus on operational excellence, financial governance, and growth strategies.

• Strategic initiatives are underway to reposition the business for growth and profitability, including cost optimization, customer growth strategies, and technology enhancements.

• Early signs of improvement are visible in key metrics such as increased order values, reduced call wait times, and improved margins, despite Q1 results being below expectations.

• PetMed Express is a direct-to-consumer pet pharmacy and online provider of pet medications, food, and supplies, with a product line of about 15,000 items for dogs, cats, and horses.

• The average purchase value was approximately $97 for both Q1 FY25 and Q1 FY24.

Financial highlights

• Net sales for Q1 FY25 were $68 million, down 13.2% year-over-year from $78.2 million, primarily due to lower prescription medication sales.

• Gross profit margin declined to 26.4% from 28.8% year-over-year, with gross profit at $18.0 million, impacted by higher promotional activity.

• Adjusted EBITDA was a loss of $1.5 million, compared to a positive $3.1 million last year, reflecting lower sales and gross profit.

• Net income was $3.8 million ($0.18 per diluted share), versus a net loss of $1.1 million ($0.06 per share) last year, driven by an $8.7 million to $10 million decrease in stock compensation expense.

• Cash and equivalents stood at $46 million at quarter-end, down from $55.3 million at March 31, 2024, but increased to $53 million in early August, with no debt.

Outlook and guidance

• Stabilization in revenue, conversion rates, and margins observed from April through July, with continued improvement expected.

• New acquisition marketing campaigns launching in August are anticipated to accelerate sales growth and profitability.

• Leadership remains confident in capturing more customers and increasing transaction frequency through technology and marketing initiatives.

• Macroeconomic factors such as inflation, higher interest rates, and supply chain volatility are expected to continue impacting operations and consumer demand for the remainder of FY25.

• The company expects ongoing challenges in revenue growth due to increased competition and price sensitivity among consumers.